SNDX: Short Interest Retreats as Options Turn Defensive After Earnings Beat

Syndax Pharmaceuticals stock jumped 9% on November 3 after reporting results that beat estimates, yet the stock remains down 19% over the past month, leaving it trading at a steep discount to analyst targets while shorts hold significant positions and options traders have abruptly shifted toward hedging.

The positioning story here is a study in contrasts. Short interest has been declining steadily, falling from roughly 20.2 million shares in late October to 17.9 million, a drop of about 11% over the past month, now representing about 20.6% of the free float. That is still a heavy short position by any measure. Yet the lending market tells a permissive story. Availability has expanded to 414% of short interest, well above the 52-week floor of 211%, meaning lenders hold roughly four shares available for every one already borrowed. Cost to borrow is minimal at 0.54%. There is no squeeze pressure in the borrow market, and the gradual unwinding of short positions suggests covering rather than fresh conviction either way. What complicates that picture sharply is options. The put/call ratio jumped to 0.42 on November 3, nearly three standard deviations above its 20-day mean of 0.15. That is close to the 52-week high of 0.47. For a stock that spent most of October trading with a PCR below 0.13, the sudden surge in put demand is a notable shift in tone, arriving the same day the stock rallied hard.

Analysts remain constructively positioned but have been trimming targets all year. HC Wainwright lowered its target to $36 from $38 on November 3, maintaining its Buy rating. JP Morgan has the stock at Overweight with a $40 target, set in August, and UBS also holds a Buy with a $33 target from the same period. The mean target across the consensus is $37.27, implying around 161% upside to the current price of $14.29. That gap reflects the structural nature of this stock: it is priced as a binary on pipeline execution, not on current fundamentals. The company has no meaningful revenue yet, so the price-to-earnings and EV/EBITDA multiples are deeply negative and not analytically useful here. The bull case, per the Benzinga framework, centres on Revuforj's AML data: 97% complete remission rates in frontline combinations and 86% objective response in real-world monotherapy, with the axatilimab franchise in cGVHD providing a separate commercial runway. The bear case is straightforward: clinical-stage risk, dilution exposure from financing needs, and profitability that the most optimistic analysts model only by 2032. The ORTEX short score of 67.3 has been easing from above 70 two weeks ago, consistent with the short interest pullback, but still ranks in just the 13th percentile on short score rank, flagging meaningful residual bearish positioning.

Medicaid reimbursement data from the Centers for Medicare and Medicaid Services offers a concrete data point on early commercial traction. Medicaid dollars reimbursed for Syndax's drugs were up 527% on the same quarter a year earlier in the January 2026 period, with units reimbursed up 627%. These are small absolute numbers: $8.7 million in dollars and 15,427 units. But the year-on-year growth rate reflects genuine commercial uptake from a near-zero base, rather than a mature franchise showing expansion. None of the available alt-data datasets have been measured to lead the company's reported financial figures, so this reading is context, not a signal about the upcoming print.

The institutional register is worth noting for its mix. BlackRock holds 10.1% of shares and added 765,580 shares in the quarter to September 30. State Street Investment Management added 1.23 million shares in the same period, lifting its stake to 6.3%. Goldman Sachs holds 6.1%, unchanged. The most recent insider activity was a director exercising and selling 8,000 shares under a pre-arranged 10b5-1 plan on October 29, netting a small gain. All significant insider trades in the data are plan-based, limiting their read-through as conviction signals.

The November 2 earnings event produced a 4.7% single-day move, modest relative to the biotech norm for binary data reads. The next scheduled print is not until March 2027, leaving the stock to trade on pipeline updates and cash runway commentary through the winter. With shorts covering slowly, options hedging at a near-extreme reading, and the stock still 19% below its October level despite this week's bounce, the key variable to watch is whether the put buying reflects genuine caution about the durability of the rally, or simply late hedging after a gap-up open.